Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.

Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS.

N Engl J Med. 2006 Dec 14;355(24):2513-22.

2.

Comparative efficacy of inactivated and live attenuated influenza vaccines.

Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC.

N Engl J Med. 2009 Sep 24;361(13):1260-7. doi: 10.1056/NEJMoa0808652.

3.

Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines.

Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS.

J Infect Dis. 2008 Aug 1;198(3):312-7. doi: 10.1086/589885.

4.

Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.

Levine MZ, Martin JM, Gross FL, Jefferson S, Cole KS, Archibald CA, Nowalk MP, Susick M, Moehling K, Spencer S, Chung JR, Flannery B, Zimmerman RK.

Clin Vaccine Immunol. 2016 Oct 4;23(10):831-839. Print 2016 Oct.

5.

Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.

Helmeke C, Gräfe L, Irmscher HM, Gottschalk C, Karagiannis I, Oppermann H.

PLoS One. 2015 Apr 17;10(4):e0122910. doi: 10.1371/journal.pone.0122910. eCollection 2015.

6.

Influenza vaccine effectiveness in preventing hospitalizations with laboratory-confirmed influenza in Greece during the 2014-2015 season: A test-negative study.

Lytras T, Kossyvakis A, Melidou A, Andreopoulou A, Exindari M, Gioula G, Kalliaropoulos A, Tryfinopoulou K, Pogka V, Spala G, Malisiovas N, Mentis A.

J Med Virol. 2016 Nov;88(11):1896-904. doi: 10.1002/jmv.24551. Epub 2016 Apr 26.

PMID:
27088266
7.

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.

BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343.

8.

Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.

Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM.

J Infect Dis. 2009 Dec 15;200(12):1861-9. doi: 10.1086/648406.

PMID:
19909082
9.

Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.

Sugaya N, Nerome K, Ishida M, Matsumoto M, Mitamura K, Nirasawa M.

JAMA. 1994 Oct 12;272(14):1122-6.

PMID:
7933325
10.

A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.

Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.

Vaccine. 2011 Nov 21;29(50):9391-7. doi: 10.1016/j.vaccine.2011.09.109. Epub 2011 Oct 6.

PMID:
21983154
11.

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.

Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.

Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.

PMID:
17698577
12.

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.

N Engl J Med. 1998 May 14;338(20):1405-12.

13.

Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.

Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD; CAIV-T Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):870-9.

PMID:
17006279
14.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, Treanor JJ.

BMC Infect Dis. 2010 Mar 17;10:71. doi: 10.1186/1471-2334-10-71.

15.

Live attenuated seasonal and pandemic influenza vaccine in school-age children: a randomized controlled trial.

Klick B, Durrani S, Chan KH, Ip DK, Chou ES, Kwok HK, Ng S, Chiu SS, Peiris JS, Leung GM, Cowling BJ.

Vaccine. 2013 Apr 8;31(15):1937-43. doi: 10.1016/j.vaccine.2013.02.017. Epub 2013 Feb 19.

PMID:
23434387
16.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
17.

Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results.

Pebody R, Warburton F, Andrews N, Ellis J, von Wissmann B, Robertson C, Yonova I, Cottrell S, Gallagher N, Green H, Thompson C, Galiano M, Marques D, Gunson R, Reynolds A, Moore C, Mullett D, Pathirannehelage S, Donati M, Johnston J, de Lusignan S, McMenamin J, Zambon M.

Euro Surveill. 2015;20(36). doi: 10.2807/1560-7917.ES.2015.20.36.30013.

18.

Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season.

Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK; Marshfield Influenza Study Group.

J Infect Dis. 2009 Jan 15;199(2):159-67. doi: 10.1086/595861.

PMID:
19086915
19.

A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF.

J Infect Dis. 1994 Jan;169(1):68-76.

PMID:
8277200
20.

Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.

Hung IF, Zhang AJ, To KK, Chan JF, Li P, Wong TL, Zhang R, Chan TC, Chan BC, Wai HH, Chan LW, Fong HP, Hui RK, Kong KL, Leung AC, Ngan AH, Tsang LW, Yeung AP, Yiu GC, Yung W, Lau JY, Chen H, Chan KH, Yuen KY.

Lancet Infect Dis. 2016 Feb;16(2):209-18. doi: 10.1016/S1473-3099(15)00354-0. Epub 2015 Nov 9.

PMID:
26559482

Supplemental Content

Support Center